Genfit S.A. (FRA:XUP)

Market Cap	223.98M
Revenue (ttm)	45.13M
Net Income (ttm)	-38.76M
Shares Out	n/a
EPS (ttm)	-0.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	10
Open	4.230
Previous Close	3.920
Day's Range	4.230 - 4.230
52-Week Range	2.846 - 4.230
Beta	n/a
RSI	68.31
Earnings Date	Dec 23, 2025

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 180
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: XUP